Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:GRAY NYSE:IBIO NASDAQ:NRBO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$1.13+9.7%$0.77$0.38▼$83.52$13.16M0.741.37 million shs1.09 million shsGRAYGraybug Vision$3.19-6.0%$3.01$5.00▼$22.12$5.01M1.22,165 shs71,174 shsIBIOiBio$0.79-7.3%$0.79$0.56▼$6.89$16.03M0.891.37 million shs418,109 shsNRBONeuroBo Pharmaceuticals$1.03-4.6%$0.79$2.08▼$4.41$8.87M-0.2639,605 shs99,507 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma+11.96%+26.30%+37.61%+22.62%-98.73%GRAYGraybug Vision-1.97%+4.12%+3.11%+96.67%-20.29%IBIOiBio-1.42%+2.41%+2.55%+4.84%-69.82%NRBONeuroBo Pharmaceuticals+1.89%+4.85%+56.50%+56.30%-59.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$1.13+9.7%$0.77$0.38▼$83.52$13.16M0.741.37 million shs1.09 million shsGRAYGraybug Vision$3.19-6.0%$3.01$5.00▼$22.12$5.01M1.22,165 shs71,174 shsIBIOiBio$0.79-7.3%$0.79$0.56▼$6.89$16.03M0.891.37 million shs418,109 shsNRBONeuroBo Pharmaceuticals$1.03-4.6%$0.79$2.08▼$4.41$8.87M-0.2639,605 shs99,507 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma+11.96%+26.30%+37.61%+22.62%-98.73%GRAYGraybug Vision-1.97%+4.12%+3.11%+96.67%-20.29%IBIOiBio-1.42%+2.41%+2.55%+4.84%-69.82%NRBONeuroBo Pharmaceuticals+1.89%+4.85%+56.50%+56.30%-59.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00BuyN/AN/AGRAYGraybug Vision 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00531.87% UpsideNRBONeuroBo Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRAY, IBIO, AEON, and NRBO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AEONAEON BiopharmaAegisSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AGRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/AIBIOiBio$400K40.07N/AN/A$1.41 per share0.56NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$6.086.28N/AN/AN/AN/A-994.63%11/12/2025 (Estimated)GRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/AIBIOiBio-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/ANRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%11/5/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22GRAYGraybug VisionN/A10.7310.72IBIOiBio0.051.761.76NRBONeuroBo PharmaceuticalsN/A2.412.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%GRAYGraybug Vision49.94%IBIOiBio7.90%NRBONeuroBo Pharmaceuticals1.37%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%GRAYGraybug Vision7.94%IBIOiBio0.58%NRBONeuroBo Pharmaceuticals1.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.64 million74.37 millionNot OptionableGRAYGraybug Vision271.57 million20.25 millionNot OptionableIBIOiBio10020.26 million9.82 millionN/ANRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionableGRAY, IBIO, AEON, and NRBO HeadlinesRecent News About These CompaniesMTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…December 4, 2024 | msn.comNeuroBo Pharmaceuticals Rebrands as MetaVia: Strategic Positioning and Growth Potential Highlighted in Buy Rating by Jason McCarthyNovember 21, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals rebrands to become MetaViaNovember 19, 2024 | fiercepharma.comFNeuroBo Pharmaceuticals Rebrands Amidst Strategic ChangesNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals announces relignment, change nameNovember 19, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNovember 18, 2024 | prnewswire.comNRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024November 13, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in NovemberNovember 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap EventNovember 12, 2024 | bignewsnetwork.comBNeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNovember 4, 2024 | prnewswire.comNeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comNRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…October 1, 2024 | msn.comNeuroBo Pharmaceuticals to Participate in Investor Conferences in OctoberOctober 1, 2024 | prnewswire.comNeuroBo Pharma Announces Positive Results From Phase 1 Trial Of DA-1726 In Obesity TreatmentSeptember 30, 2024 | markets.businessinsider.comWe're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn RateSeptember 30, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesitySeptember 30, 2024 | prnewswire.comNeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comNRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24…August 21, 2024 | msn.comBuy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental PipelineAugust 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRAY, IBIO, AEON, and NRBO Company DescriptionsAEON Biopharma NASDAQ:AEON$1.13 +0.10 (+9.71%) Closing price 04:00 PM EasternExtended Trading$1.10 -0.03 (-2.30%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Graybug Vision NASDAQ:GRAY$3.19 -0.20 (-6.02%) As of 10/8/2025Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.iBio NYSE:IBIO$0.79 -0.06 (-7.34%) Closing price 04:00 PM EasternExtended Trading$0.78 -0.01 (-0.92%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.NeuroBo Pharmaceuticals NASDAQ:NRBO$1.03 -0.05 (-4.63%) As of 10/9/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
